Advertisement

Topics

Gilead, Insitro in $250M machine learning partnership to develop NASH drugs

10:32 EDT 16 Apr 2019 | MedCity News

graphic design of a liver

The deal comes days after Gilead partnered on clinical development in NASH with Denmark’s Novo Nordisk, and two months after the high-profile failure of a Phase III study in the disease.

Original Article: Gilead, Insitro in $250M machine learning partnership to develop NASH drugs

NEXT ARTICLE

More From BioPortfolio on "Gilead, Insitro in $250M machine learning partnership to develop NASH drugs"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...